Valeant Claims Progress, Asks Investors For Patience
Executive Summary
The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
You may also be interested in...
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.